Results 21 to 30 of about 3,710 (152)

Protective Effects of Riociguat Against Contrast-Induced Nephropathy: An Experimental and Machine Learning-Based Study in Rats. [PDF]

Kaohsiung J Med Sci
ABSTRACT Contrast‐induced nephropathy (CIN) is an important cause of acute kidney injury following exposure to iodinated contrast media, and effective preventive strategies remain limited. This study investigated the renoprotective effects of riociguat, a soluble guanylate cyclase stimulator, in an experimental rat model of CIN and explored machine ...
Tascanov MB, Toprak K, Turedi S, Koyuncu İ, Tanrıverdi Z, Dedeoglu NF, Fedai H, Bicer A, Altıparmak İH, Demirbag R, Sarıısık G.   +10 more
europepmc   +2 more sources

Long-Term Supervised Cardiac Rehabilitation After Balloon Pulmonary Angioplasty Improved Residual Exercise Pulmonary Hypertension in Patients With Chronic Thromboembolic Pulmonary Hypertension: A Two-Case Report. [PDF]

Pulm Circ
ABSTRACT Abnormal pulmonary hemodynamics during exercise may persist even after balloon pulmonary angioplasty (BPA) for inoperable chronic thromboembolic pulmonary hypertension (CTEPH). We report two female patients who underwent long‐term supervised outpatient cardiac rehabilitation (CR) after BPA with continuous pulmonary vasodilators.
Suzuki Y, Nakano Y, Okazaki K, Ito M, Yoshimori A, Tsunoda M, Yoshida M, Mitsui T, Adachi S, Kimura A.   +9 more
europepmc   +2 more sources

The Role of Medical Therapy Before and After Balloon Pulmonary Angioplasty: CTEPH AC Registry Across Japan. [PDF]

Pulm Circ
ABSTRACT We aimed to evaluate the role of medical therapy before and after balloon pulmonary angioplasty (BPA) for non‐operable chronic thromboembolic pulmonary hypertension (CTEPH) in the modern management era. This Japanese nationwide, multicenter, prospective observational registry, including 37 centers, analyzed data newly registered from August ...
Sakamoto-Iwata M, Taniguchi Y, Masaki K, Hosokawa K, Adachi S, Inami T, Yamashita J, Ogino H, Hatano M, Tsujino I, Yaoita N, Ikeda N, Shimokawahara H, Tanabe N, Kubota K, Shigeta A, Ogihara Y, Horimoto K, Dohi Y, Hiraide T, Kawakami T, Tamura Y, Fukumoto Y, Abe K.   +23 more
europepmc   +2 more sources

Balloon pulmonary angioplasty combined with riociguat for the treatment of inoperable chronic thromboembolic pulmonary hypertension (PRACTICE study): study protocol for a randomized controlled trial

Trials, 2021
Background Management of inoperable chronic thromboembolic pulmonary hypertension (CTEPH) remains a clinical challenge. Currently, riociguat, a soluble guanylate-cyclase stimulator is recommended by international guidelines.
Qin-Hua Zhao, Su-Gang Gong, Jing He, Ping Yuan, Wen-Hui Wu, Ci-Jun Luo, Rong Jiang, Rui Zhang, Hong-Ling Qiu, Hui-Ting Li, Yuan Li, Jin-Ming Liu, Lan Wang   +12 more
doaj   +1 more source

Optimization of specific therapy for pulmonary hypertension: the possibilities of riociguat

Терапевтический архив, 2021
Pulmonary hypertension (PH) is a severe and often rapidly progressive disease with fatal outcome. Endothelial dysfunction in PH is associated with decreased nitric oxide production.
Tamila V. Martynyuk, Anton A. Shmalts, Sergey V. Gorbachevsky, Irina E. Chazova   +3 more
doaj   +1 more source

Soluble guanylate cyclase stimulation prevents fibrotic tissue remodeling and improves survival in salt-sensitive Dahl rats. [PDF]

PLoS ONE, 2011
A direct pharmacological stimulation of soluble guanylate cyclase (sGC) is an emerging therapeutic approach to the management of various cardiovascular disorders associated with endothelial dysfunction.
Sandra Geschka, Axel Kretschmer, Yuliya Sharkovska, Oleg V Evgenov, Bettina Lawrenz, Andreas Hucke, Berthold Hocher, Johannes-Peter Stasch   +7 more
doaj   +1 more source

RISE-SSc: Riociguat in diffuse cutaneous systemic sclerosis [PDF]

, 2017
RISE-SSc is a randomized, double-blind, placebo-controlled phase 2 study investigating the efficacy and safety of riociguat in patients with diffuse cutaneous systemic sclerosis (dcSSc).
Khanna, D, Allanore, Yannick, Khanna, Dinesh, Distler, Oliver, de Oliveira Pena, Janethe, de Oliveira Pena, J, Distler, O, Matucci-Cerinic, Marco, Matucci-Cerinic, M, Denton, Chris, Pope, J, Pope, Janet, Denton, C, Allanore, Y   +13 more
core   +2 more sources

Efficacy and safety of riociguat replacing PDE-5is for patients with pulmonary arterial hypertension: A systematic review and meta-analysis

Frontiers in Pharmacology, 2023
Introduction: Pulmonary arterial hypertension (PAH) is a rare and progressive disease. Some patients treated with phosphodiesterase type 5 inhibitors (PDE-5is) fail to reach treatment goals. As a novel soluble guanylate cyclase agonist, riociguat acts on
Yu-Yang Liu, Yi-Yang Qu, Shang Wang, Ci-Jun Luo, Hong-Ling Qiu, Hui-Ting Li, Ping Yuan, Lan Wang, Jin-Ling Li, Jin-Ling Li, Rong Jiang, Rui Zhang   +11 more
doaj   +1 more source

Riociguat: Clinical research and evolving role in therapy [PDF]

, 2020
Riociguat is a first-in-class soluble guanylate cyclase stimulator, approved for the treatment of adults with pulmonary arterial hypertension (PAH), inoperable chronic thromboembolic pulmonary hypertension (CTEPH), or persistent or recurrent CTEPH after ...
Klinger, James, Klinger, James R, Chakinala, Murali, David Langleben, James R. Klinger, Langleben, David, Rosenkranz, Stephan, Sitbon, Olivier, Stephan Rosenkranz, Murali M. Chakinala, Chakinala, Murali M, Olivier Sitbon   +11 more
core   +1 more source

Pharmacokinetic interaction of riociguat and antiretroviral combination regimens in HIV-1-infected adults

Pulmonary Circulation, 2019
Riociguat, a first-in-class soluble guanylate cyclase stimulator, is approved for the treatment of pulmonary arterial hypertension (PAH), a serious potential complication of human immunodeficiency virus (HIV) infection. This open-label study investigated
Edwin DeJesus, Soundos Saleh, Sue Cheng, Dorina van der Mey, Corina Becker, Reiner Frey, Sigrun Unger, Wolfgang Mueck   +7 more
doaj   +1 more source